http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 22 Aug 2025 09:07:51 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Intl+Ratings/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Raised+to+AUD2.19+at+Canaccord+Genuity/25238538.html Canaccord Genuity analyst Elyse Shapiro raised the price target on Cogstate (CGS:AU) (OTC: COGZF) to AUD2.19 (from AUD1.85) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Raised+to+AUD2.19+at+Canaccord+Genuity/25238538.html Fri, 22 Aug 2025 09:07:51 -0400 COGZF http://www.streetinsider.com/Intl+Ratings/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Raised+to+AUD2.19+at+Canaccord+Genuity/25238538.html Canaccord Genuity analyst Elyse Shapiro raised the price target on Cogstate (CGS:AU) (OTC: COGZF) to AUD2.19 (from AUD1.85) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Raised+to+AUD2.19+at+Canaccord+Genuity/25238538.html Fri, 22 Aug 2025 09:07:51 -0400 COGZF http://www.streetinsider.com/Analyst+PT+Change/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Raised+to+AUD2.19+at+Canaccord+Genuity/25238538.html Canaccord Genuity analyst Elyse Shapiro raised the price target on Cogstate (CGS:AU) (OTC: COGZF) to AUD2.19 (from AUD1.85) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Raised+to+AUD2.19+at+Canaccord+Genuity/25238538.html Fri, 22 Aug 2025 09:07:51 -0400 COGZF http://www.streetinsider.com/Analyst+PT+Change/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Raised+to+AUD2.19+at+Canaccord+Genuity/25238538.html Canaccord Genuity analyst Elyse Shapiro raised the price target on Cogstate (CGS:AU) (OTC: COGZF) to AUD2.19 (from AUD1.85) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Raised+to+AUD2.19+at+Canaccord+Genuity/25238538.html Fri, 22 Aug 2025 09:07:51 -0400 COGZF http://www.streetinsider.com/Intl+Ratings/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Raised+to+AUD1.85+at+Canaccord+Genuity/24969204.html Canaccord Genuity analyst Elyse Shapiro raised the price target on Cogstate (CGS:AU) (OTC: COGZF) to AUD1.85 (from AUD1.50) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Raised+to+AUD1.85+at+Canaccord+Genuity/24969204.html Tue, 24 Jun 2025 09:43:52 -0400 COGZF http://www.streetinsider.com/Intl+Ratings/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Raised+to+AUD1.85+at+Canaccord+Genuity/24969204.html Canaccord Genuity analyst Elyse Shapiro raised the price target on Cogstate (CGS:AU) (OTC: COGZF) to AUD1.85 (from AUD1.50) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Raised+to+AUD1.85+at+Canaccord+Genuity/24969204.html Tue, 24 Jun 2025 09:43:52 -0400 COGZF http://www.streetinsider.com/Analyst+PT+Change/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Raised+to+AUD1.85+at+Canaccord+Genuity/24969204.html Canaccord Genuity analyst Elyse Shapiro raised the price target on Cogstate (CGS:AU) (OTC: COGZF) to AUD1.85 (from AUD1.50) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Raised+to+AUD1.85+at+Canaccord+Genuity/24969204.html Tue, 24 Jun 2025 09:43:52 -0400 COGZF http://www.streetinsider.com/Analyst+PT+Change/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Raised+to+AUD1.85+at+Canaccord+Genuity/24969204.html Canaccord Genuity analyst Elyse Shapiro raised the price target on Cogstate (CGS:AU) (OTC: COGZF) to AUD1.85 (from AUD1.50) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Raised+to+AUD1.85+at+Canaccord+Genuity/24969204.html Tue, 24 Jun 2025 09:43:52 -0400 COGZF http://www.streetinsider.com/Press+Releases/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html <p>Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9vEfcRyZkqBzxeQhO1r79EoteYm2NMh8XmKkYCS7K0rXBpPfB8f86HURIh_kx-_9dzuAUh2tvzUj1SfuuaUkgQ==" rel="nofollow" target="_blank">Cogstate</a>, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies.</p> <p>Dr. Sink will use her extensive experience in Alzheimer’s disease drug development—gained from leading global trials and programs—to advise biopharmaceutical leaders through strategic trial http://www.streetinsider.com/Press+Releases/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html Mon, 14 Oct 2024 11:14:00 -0400 A.40151759 CGS COGZF O.00050368 O.01130046 http://www.streetinsider.com/Press+Releases/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html <p>Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9vEfcRyZkqBzxeQhO1r79EoteYm2NMh8XmKkYCS7K0rXBpPfB8f86HURIh_kx-_9dzuAUh2tvzUj1SfuuaUkgQ==" rel="nofollow" target="_blank">Cogstate</a>, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies.</p> <p>Dr. Sink will use her extensive experience in Alzheimer’s disease drug development—gained from leading global trials and programs—to advise biopharmaceutical leaders through strategic trial http://www.streetinsider.com/Press+Releases/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html Mon, 14 Oct 2024 11:14:00 -0400 A.40151759 CGS COGZF O.00050368 O.01130046 http://www.streetinsider.com/Press+Releases/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html <p>Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9vEfcRyZkqBzxeQhO1r79EoteYm2NMh8XmKkYCS7K0rXBpPfB8f86HURIh_kx-_9dzuAUh2tvzUj1SfuuaUkgQ==" rel="nofollow" target="_blank">Cogstate</a>, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies.</p> <p>Dr. Sink will use her extensive experience in Alzheimer’s disease drug development—gained from leading global trials and programs—to advise biopharmaceutical leaders through strategic trial http://www.streetinsider.com/Press+Releases/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html Mon, 14 Oct 2024 11:14:00 -0400 A.40151759 CGS COGZF O.00050368 O.01130046 http://www.streetinsider.com/Press+Releases/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html <p>Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9vEfcRyZkqBzxeQhO1r79EoteYm2NMh8XmKkYCS7K0rXBpPfB8f86HURIh_kx-_9dzuAUh2tvzUj1SfuuaUkgQ==" rel="nofollow" target="_blank">Cogstate</a>, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies.</p> <p>Dr. Sink will use her extensive experience in Alzheimer’s disease drug development—gained from leading global trials and programs—to advise biopharmaceutical leaders through strategic trial http://www.streetinsider.com/Press+Releases/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html Mon, 14 Oct 2024 11:14:00 -0400 A.40151759 CGS COGZF O.00050368 O.01130046 http://www.streetinsider.com/Press+Releases/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html <p>Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9vEfcRyZkqBzxeQhO1r79EoteYm2NMh8XmKkYCS7K0rXBpPfB8f86HURIh_kx-_9dzuAUh2tvzUj1SfuuaUkgQ==" rel="nofollow" target="_blank">Cogstate</a>, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies.</p> <p>Dr. Sink will use her extensive experience in Alzheimer’s disease drug development—gained from leading global trials and programs—to advise biopharmaceutical leaders through strategic trial http://www.streetinsider.com/Press+Releases/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html Mon, 14 Oct 2024 11:14:00 -0400 A.40151759 CGS COGZF O.00050368 O.01130046 http://www.streetinsider.com/Globe+Newswire/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html <p>Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9vEfcRyZkqBzxeQhO1r79EoteYm2NMh8XmKkYCS7K0rXBpPfB8f86HURIh_kx-_9dzuAUh2tvzUj1SfuuaUkgQ==" rel="nofollow" target="_blank">Cogstate</a>, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies.</p> <p>Dr. Sink will use her extensive experience in Alzheimer’s disease drug development—gained from leading global trials and programs—to advise biopharmaceutical leaders through strategic trial http://www.streetinsider.com/Globe+Newswire/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html Mon, 14 Oct 2024 11:14:00 -0400 A.40151759 CGS COGZF O.00050368 O.01130046 http://www.streetinsider.com/Globe+Newswire/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html <p>Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9vEfcRyZkqBzxeQhO1r79EoteYm2NMh8XmKkYCS7K0rXBpPfB8f86HURIh_kx-_9dzuAUh2tvzUj1SfuuaUkgQ==" rel="nofollow" target="_blank">Cogstate</a>, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies.</p> <p>Dr. Sink will use her extensive experience in Alzheimer’s disease drug development—gained from leading global trials and programs—to advise biopharmaceutical leaders through strategic trial http://www.streetinsider.com/Globe+Newswire/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html Mon, 14 Oct 2024 11:14:00 -0400 A.40151759 CGS COGZF O.00050368 O.01130046 http://www.streetinsider.com/Globe+Newswire/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html <p>Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9vEfcRyZkqBzxeQhO1r79EoteYm2NMh8XmKkYCS7K0rXBpPfB8f86HURIh_kx-_9dzuAUh2tvzUj1SfuuaUkgQ==" rel="nofollow" target="_blank">Cogstate</a>, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies.</p> <p>Dr. Sink will use her extensive experience in Alzheimer’s disease drug development—gained from leading global trials and programs—to advise biopharmaceutical leaders through strategic trial http://www.streetinsider.com/Globe+Newswire/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html Mon, 14 Oct 2024 11:14:00 -0400 A.40151759 CGS COGZF O.00050368 O.01130046 http://www.streetinsider.com/Globe+Newswire/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html <p>Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9vEfcRyZkqBzxeQhO1r79EoteYm2NMh8XmKkYCS7K0rXBpPfB8f86HURIh_kx-_9dzuAUh2tvzUj1SfuuaUkgQ==" rel="nofollow" target="_blank">Cogstate</a>, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies.</p> <p>Dr. Sink will use her extensive experience in Alzheimer’s disease drug development—gained from leading global trials and programs—to advise biopharmaceutical leaders through strategic trial http://www.streetinsider.com/Globe+Newswire/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html Mon, 14 Oct 2024 11:14:00 -0400 A.40151759 CGS COGZF O.00050368 O.01130046 http://www.streetinsider.com/Globe+Newswire/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html <p>Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9vEfcRyZkqBzxeQhO1r79EoteYm2NMh8XmKkYCS7K0rXBpPfB8f86HURIh_kx-_9dzuAUh2tvzUj1SfuuaUkgQ==" rel="nofollow" target="_blank">Cogstate</a>, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies.</p> <p>Dr. Sink will use her extensive experience in Alzheimer’s disease drug development—gained from leading global trials and programs—to advise biopharmaceutical leaders through strategic trial http://www.streetinsider.com/Globe+Newswire/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html Mon, 14 Oct 2024 11:14:00 -0400 A.40151759 CGS COGZF O.00050368 O.01130046 http://www.streetinsider.com/Intl+Ratings/Canaccord+Genuity+Reiterates+Buy+Rating+on+Cogstate+%28CGS%3AAU%29+%28COGZF%29/23338876.html <p>Canaccord Genuity analyst Elyse Shapiro reiterated a Buy rating and AUD1.80 price target on Cogstate (CGS:AU) (OTC: COGZF).</p> http://www.streetinsider.com/Intl+Ratings/Canaccord+Genuity+Reiterates+Buy+Rating+on+Cogstate+%28CGS%3AAU%29+%28COGZF%29/23338876.html Sun, 09 Jun 2024 01:34:07 -0400 COGZF http://www.streetinsider.com/Intl+Ratings/Canaccord+Genuity+Reiterates+Buy+Rating+on+Cogstate+%28CGS%3AAU%29+%28COGZF%29/23338876.html <p>Canaccord Genuity analyst Elyse Shapiro reiterated a Buy rating and AUD1.80 price target on Cogstate (CGS:AU) (OTC: COGZF).</p> http://www.streetinsider.com/Intl+Ratings/Canaccord+Genuity+Reiterates+Buy+Rating+on+Cogstate+%28CGS%3AAU%29+%28COGZF%29/23338876.html Sun, 09 Jun 2024 01:34:07 -0400 COGZF http://www.streetinsider.com/Intl+Ratings/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Lowered+to+AUD1.80+at+Canaccord+Genuity/22816264.html Canaccord Genuity analyst Elyse Shapiro lowered the price target on Cogstate (CGS:AU) (OTC: COGZF) to AUD1.80 (from AUD2.10) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Lowered+to+AUD1.80+at+Canaccord+Genuity/22816264.html Thu, 22 Feb 2024 09:56:33 -0400 COGZF http://www.streetinsider.com/Intl+Ratings/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Lowered+to+AUD1.80+at+Canaccord+Genuity/22816264.html Canaccord Genuity analyst Elyse Shapiro lowered the price target on Cogstate (CGS:AU) (OTC: COGZF) to AUD1.80 (from AUD2.10) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Lowered+to+AUD1.80+at+Canaccord+Genuity/22816264.html Thu, 22 Feb 2024 09:56:33 -0400 COGZF http://www.streetinsider.com/Analyst+PT+Change/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Lowered+to+AUD1.80+at+Canaccord+Genuity/22816264.html Canaccord Genuity analyst Elyse Shapiro lowered the price target on Cogstate (CGS:AU) (OTC: COGZF) to AUD1.80 (from AUD2.10) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Lowered+to+AUD1.80+at+Canaccord+Genuity/22816264.html Thu, 22 Feb 2024 09:56:33 -0400 COGZF http://www.streetinsider.com/Analyst+PT+Change/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Lowered+to+AUD1.80+at+Canaccord+Genuity/22816264.html Canaccord Genuity analyst Elyse Shapiro lowered the price target on Cogstate (CGS:AU) (OTC: COGZF) to AUD1.80 (from AUD2.10) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Lowered+to+AUD1.80+at+Canaccord+Genuity/22816264.html Thu, 22 Feb 2024 09:56:33 -0400 COGZF http://www.streetinsider.com/Intl+Ratings/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Lowered+to+AUD2.20+at+Canaccord+Genuity/21283445.html Canaccord Genuity analyst Elyse Shapiro lowered the price target on Cogstate (CGS:AU) (OTC: COGZF) to AUD2.20 (from AUD2.40) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Cogstate+%28CGS%3AAU%29+%28COGZF%29+PT+Lowered+to+AUD2.20+at+Canaccord+Genuity/21283445.html Mon, 27 Feb 2023 10:36:03 -0400 COGZF